Relmada Therapeutics's total assets for Q2 2025 were $21.12M, a decrease of -23.71% from the previous quarter. RLMD total liabilities were $5.17M for the fiscal quarter, a -1.38% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.